Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
February 2013 Volume 7 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
February 2013 Volume 7 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Silencing P12CDK2AP1 with a lentivirus promotes HaCaT cell proliferation

  • Authors:
    • Moyi Sun
    • Jun Zheng
    • Hui Xue
    • Yuegui Jiang
    • Chunnan Li
    • Jianhu Li
    • Wei Jin
    • Minzhi Shen
    • Xiangming Yang
    • Qianwei Ni
  • View Affiliations / Copyright

    Affiliations: Department of Oral and Maxillofacial Surgery, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Orthodontics, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Conservative Dentistry, School of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Oral and Maxillofacial Surgery, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Biochemistry and Molecular Biology and The State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
  • Pages: 471-475
    |
    Published online on: November 27, 2012
       https://doi.org/10.3892/mmr.2012.1205
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The tumor suppressor P12CDK2AP1 negatively regulates cyclin-dependent kinase 2 (CDK2) activities and suppresses DNA replication. Notably, P12CDK2AP1 is known to be downregulated in head and neck squamous cell carcinomas (HNSCCs). Silencing of specific gene expression by small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) using expression vectors and retroviruses has become a powerful tool for the genetic analysis of mammalian cells. In the present study, we utilized lentivirus‑mediated shRNA for functional gene knockdown in normal human skin keratinocytes (HaCaT) cells in order to assess the potential role of P12CDK2AP1 in HNSCCs. Lentivirus‑mediated RNA interference (RNAi) effectively reduced endogenous P12CDK2AP1 expression in HaCaT cells and significantly promoted HaCaT cell proliferation in vitro. Lentiviral vectors have the ability to infect dividing and non-dividing cells as well as to achieve long‑term multilineage gene expression. Thus, additional studies are needed to investigate the use of such vectors as a therapeutic tool for the delivery of siRNAs.

Introduction

The various types of of head and neck cancer represent ~5% of all the cancer types, and 80–90% of these tumors constitute squamous cell carcinomas. Despite the rapid progress in the diagnosis and treatment of this disease, the overall 5-year survival of this type of cancer is among the lowest of the most common tumor types (1). Most types of human oral cancer (63.8%) exhibit either a loss or significant reduction of P12CDK2AP1 expression. Decreased P12CDK2AP1 expression has been shown to correlate with increased tumor invasion, risk of lymph node metastases, and decreased survival in patients with oral squamous cell carcinoma (2).

Human cyclin-dependent kinase 2 associated protein 1 (CDK2AP1) is a highly conserved gene. No mutations have been found in oral and esophageal types of cancer (3,4). P12CDK2AP1, originally known as deleted in oral cancer-1 (DOC-1), is identified and cloned from the Syrian hamster oral cancer model (5) and acts as a growth suppressor by negatively regulating the activity of cyclin-dependent kinase 2 (CDK2) (6). Human P12CDK2AP1 associates with DNA polymerase α/primase and mediates the phosphorylation of the large p180 catalytic subunit, suggesting that it is a potential regulator of DNA replication in the S phase of the cell cycle (3). Moreover, the ectopic expression of P12CDK2AP1 in culture cells leads to growth suppression, arrests cells in the G1 phase of the cell cycle and suppresses DNA replication (6,7). Several functional studies support the role of P12CDK2AP1 as a growth suppressor (3,5,6,8).

RNA interference (RNAi) is an evolutionarily conserved mechanism of sequence-specific post-transcriptional gene silencing mediated by double-stranded RNA molecules that match the sequence of the target gene (9). Investigators have focused on HIV-1-derived lentivirus vectors due to their ability to deliver therapeutic transgenes into a wide range of difficult-to-transfect target tissues without inducing significant humoral immune responses (10–12). In this study, we constructed a lentivirus vector for the expression of small interfering RNAs (siRNAs) in mammalian cells and demonstrated its ability to efficiently downregulate the expression of CDK2AP1 protein. The present study was undertaken to elucidate the role of P12CDK2AP1 in cell proliferation. Results demonstrated that P12CDK2AP1 silencing promotes cell proliferation in vitro.

Materials and methods

Cells, cell culture and materials

HEK293T and normal human skin keratinocytes (HaCaT) cells were obtained from the China Center for Type Culture Collection (Wuhan, China). The cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) (Invitrogen, Karlsruhe, Germany) and incubated in a humidified 37°C, 5% CO2 incubator. The primary antibody of P12CDK2AP1 was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). GAPDH antibody was purchased from Millipore (Billerica, MA, USA). SYBR-Green PCR Master mix for the quantification of CDK2AP1 mRNA was obtained from Takara (Kyoto, Japan) and oligonucleotides from Sangon (Shanghai, China).

Construction of plasmid vector for the expression of siRNA

The sequence of short hairpin RNA (shRNA) targeting the human CDK2AP1 gene was 5′-GATCTCAGTTCTGCGT TTA-3′, corresponding to the coding region positions of CDK2AP1 mRNA. The control plasmid was obtained from GenePharma Co., Ltd. (Shanghai, China). The human U6 promoter was amplified from genomic DNA and cloned in the AgeI and EcoRI sites of the pGCSIL-GFP plasmid (GeneChem, Shanghai, China). The oligonucleotides which were previously shown to induce RNAi against CDK2AP1 were cloned downstream of the U6 promoter. The sequence of the oligonucleotide (top strand) was: 5′-CcggtaGATCTCAGT TCTGCGTTTATTCAAGAGATAAACGCAGAACTGAGATCta-TTTTTg-3′. The underlined sequence corresponds to nucleotides of human open reading frame for CDK2AP1. The sequence of the construct was confirmed by automated fluorescent sequencing.

Construction of lentivirus vector for siRNA delivery

A self-inactivating lentivirus vector containing a cytomegalovirus (CMV)-driven enhanced green fluorescent protein (EGFP) reporter and a U6 promoter upstream of cloning restriction sites (AgeI and EcoRI) was purchased from GeneChem Co., Ltd. A control shRNA unrelated to human gene sequences was used as a negative control. We constructed 3 si-CDK2AP1 lentiviruses, KD-1, KD-2 and KD-3, targeting human CDK2AP1 mRNA. The following custom primers containing AgeI and EcoRI sites at their 5′ termini were used for PCR amplification: 5′-CCTATTTCCCATGATTCCT TCATA-3′ and 5′-GTAATACGGTTATCCACGCG-3′. The resulting PCR fragment was digested with AgeI and EcoRI and cloned into AgeI- and EcoRI-digested pLenti vector. Oligonucleotides for constructing the negative control and 3 si-CDK2AP1 lentiviruses were synthesized from Sangon. Correct insertions of shRNA cassettes were confirmed by restriction mapping and direct DNA sequencing. KD-3 was identified as the most efficient and was selected for this study.

Lentiviral vector infection in cultured HaCaT cells

Cells were replated at 5×103 cells/well in 96-well plates along with recombinant lentivirus encoding for shRNA against CDK2AP1 at different multiplicity of infections (MOIs) in serum-free growth medium containing 5 μg/ml polybrene at 37°C and 5% CO2. After 4 h, serum-containing growth medium was added to the cells, and there was complete replacement of growth medium after 48 h. After 3 days of post-infection, reporter gene expression was examined using fluorescent microscopy.

Real-time reverse transcription (RT)-PCR assay

Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The expression of CDK2AP1 mRNA was detected using the SYBR-Green miRNA assay (Takara) (13), and normalized using the 2−ΔΔCt method (14) relative to human β-actin (Sangon). Primer sequences and the size of the products are shown in Table I. To ensure specificity of the PCR product amplification, the melting curves for standard and sample products were analyzed. All the real-time RT-PCR assays were performed three times.

Table I

Primer sequences and the length of products for real-time RT-PCR.

Table I

Primer sequences and the length of products for real-time RT-PCR.

Gene nameOligonucleotide sequenceProduct size (bp)
CDK2AP1F: AAGAGCAACCCACCAAACC
R: ATCAACTTACAATAAACGCAGAAC
92
β-actinF: GGCGGCACCACCATGTACCCT
R: AGGGGCCGGACTCGTCATACT
202
Western blot analysis

Cells were seeded in 6-well plates and infected after 12 h. The cells were harvested 3 days following infection, washed once in phosphate-buffered saline (PBS) and lysed. Protein concentration was determined using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA). Aliquots (60 μg) were separated on a 15% SDS-PAGE and transferred to PVDF membrane. The membrane was incubated with the specific antibody followed by peroxidase-conjugated secondary antibodies. An enhanced chemiluminescence detection solution was then applied (Pierce). The relative protein level in different groups was normalized to the signal intensity of GAPDH. Quantitative analysis of the blots was performed using the NIH-ImageJ program.

Measurement of cell growth using the methyl thiazolyl tetrazolium (MTT) assay

HaCaT cells were seeded at a density of 2×103 cells/well in 96-well plates containing 0.2 ml DMEM (with 7% FBS) and cultured for 9 days. During this period, the medium was replaced with fresh complete medium every 3 days. Six wells from each group were selected randomly for the MTT assay each day. After 4 h of incubation, the reaction was stopped by adding 150 μl of dimethyl sulfoxide (DMSO; Sigma) to each well, followed by a 10-min incubation. The percentage of viable cells was determined by measuring the absorbance at 490 nm on a multiscanner reader (TECAN-spectra mini; Tecan Austria GmbH, Grödig, Austria). Cell growth curves were drawn by using average absorbance at 490 nm from 3 independent experiments.

Flow cytometric analysis of cell cycle

The cells (72 h) were harvested, washed twice with ice-cold PBS, fixed with 70% ethanol overnight at 4°C, washed and resuspended in 100 μl of PBS containing a final concentration of 50 μg/ml RNase A for 30 min at room temperature. The cells were then stained with 20 μg/ml propidium iodide in a final volume of 300 μl for 20 min. DNA content and cell cycle were analyzed using a flow cytometer (FACSCalibur; Becton-Dickinson, Franklin Lakes, NJ, USA), and ModFit and CellQuest software. The experiments were conducted three times.

Statistical analysis

The experiments were performed in triplicate and standard deviations were calculated. The statistical analysis was performed by a two-tailed paired Student’s t-test or one-way ANOVA using SPSS 11.5 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Infection efficiency of lenti-shCDK2AP1 in HaCaT cells

To determine the lentiviral infection efficiency in HaCaT cells, EGFP expression was examined by microscopy at different MOIs 3 days after infection. The efficiency of lentiviral vector infection in HaCaT cells was >90% at an MOI of 40 (Fig. 1). The percentage of EGFP-expressing cells remained relatively unchanged when MOI was >40. Based on these results, an MOI of 40 was chosen. Our data suggested that lentivirus shRNA vector pGCSIL-GFP had high efficiency for infecting HaCaT cells.

Figure 1

Determination of lentiviral infection efficiency in HaCaT cells. Infection efficiency was estimated 3 days following infection at the indicated MOIs. EGFP expression was observed under light (top panels) or fluorescence microscopy (bottom panels). (a) MOI=1; (b) MOI=20; (c) MOI=40. Scale bar, 50 μm. HaCaT cells were demonstrated to have increased EGFP expression that peaked when MOI=40.

CDK2AP1 mRNA and P12CDK2AP1 expression is efficiently inhibited in lenti-shCDK2AP1-infected HaCaT cells

The subconfluent cells were infected with either negative control or shCDK2AP1 lentivirus. Two days post-infection, the cells were collected and lysed for analysis. Real-time RT-PCR results showed the mRNA level of CDK2AP1 in HaCaT cells infected with lenti-shCDK2AP1 to be ~80% lower compared to that of HaCaT control cells (Fig. 2A). As shown in Fig. 2B and C, the level of P12CDK2AP1 expression was markedly reduced in HaCaT cells infected by lenti-shCDK2AP1 compared to that in the control cells, a fact which was consistent with the downregulation of CDK2AP1. This study indicated that lentiviral siRNA was able to provide highly efficient and specific CDK2AP1 knockdown in HaCaT cells.

Figure 2

Stable inhibition of P12CDK2AP1 expression in HaCaT cell lines by lentivirus-delivered siRNA. (A) CDK2AP1 mRNA expression was significantly decreased in the KD group (detected using real-time RT-PCR). Total RNA was isolated from HaCaT cells and HaCaT cells transfected with either CDK2AP1 siRNA expression vector or control siRNA vector. Real-time RT-PCR was performed to measure the relative copies of CDK2AP1 mRNA. The amount of each product was normalized to the housekeeping gene β-actin. CDK2AP1 mRNA in HaCaT cells decreased significantly following infection with the lentiviral shRNA vector targeting the CDK2AP1 gene. Each bar represents values from independent experiments performed in triplicate. (B) HaCaT cells were infected with pLenti/CON (lane 1), NC (lane 2) and pLenti/KD (lane 3) viruses and transduced cells were selected with Blasticidin. Western blot analysis demonstrated significant downregulation of P12CDK2AP1 expression in pLenti/KD-infected cells. GAPDH was used as an internal control. (C) Western blot analysis using NIH-ImageJ also indicated that the gray value of P12CDK2AP1 band in the KD group was significantly lower compared to that in the CON group. Each bar represents values from independent experiments performed in triplicate. **P<0.01. CON, HaCaT cells uninfected with lentivirus; NC, HaCaT cells infected with control lentivirus; KD, HaCaT cells infected with lentivirus carrying siCDK2AP1.

P12CDK2AP1 knockdown significantly promotes HaCaT cell growth in vitro

To determine whether silencing P12CDK2AP1 by RNAi had a stimulative effect on HaCaT cell growth, determination of cell proliferation was performed using the MTT assay. After 3 days of infection, lenti-shCDK2AP1 did not positively affect HaCaT cell proliferation. However, lenti-shCDK2AP1 significantly increased HaCaT cell proliferation 4–9 days following infection (Fig. 3A). Notably, the suppression of P12CDK2AP1 led to HaCaT cell growth promotion in a time-dependent manner and this stimulative effect was not observed before day 3.

Figure 3

Knockdown of P12CDK2AP1 expression by RNAi promotes HaCaT cell proliferation. (A) Proliferation curve of HaCaT cells. Cell proliferation was analyzed using MTT cell proliferation assay kits. The proliferation of HaCaT cells transfected with CDK2AP1 siRNA vector (KD) was significantly increased in a time-dependent manner, compared to cells without transfection (CON) or cells transfected with control siRNA vector (NC). (B) The flow cytometric analysis of HaCaT cells showed that the proliferation index was significantly increased in the KD group. *P<0.05.

P12CDK2AP1 knockdown affects HaCaT cell cycle transition

The different proliferation rates of HaCaT cells infected with lenti-shCDK2AP1 vs. control HaCaT cells may partly be due to differences in cell cycle regulation. Therefore, cell cycle distribution was detected using flow cytometry. On day 7, a lower number of HaCaT cells infected by lenti-shCDK2AP1 were arrested in the G0/G1 compared to the S and G2/M phases of the cell cycle (Fig. 3B).

Discussion

P12CDK2AP1 is crucial in a variety of responses, including S-phase suppression associated with growth suppression (6,7), tumor progression (15), malignant transformation (5), apoptosis and oral carcinogenesis (16). It has also been shown to be reduced or absent in various types of human oral cancer and it has been found to be a positive prognostic indicator (2). Several findings have suggested that P12CDK2AP1 loss or reduced expression contribute to the multistep nature of oral carcinogenesis, and that P12CDK2AP1 loss may constitute an event associated with tumor progression (2,6,7,17). This may raise the question as to whether blocking P12CDK2AP1 is beneficial for promoting HaCaT cell growth, and whether targeting P12CDK2AP1 signaling may serve as a novel therapeutic strategy for the treatment of HNSCCs expressing downregulated P12CDK2AP1.

Stable downregulation of gene expression via retroviral-mediated siRNA delivery has recently been described by several scientific groups (18–20). Lentiviral vector is a novel tool for human gene therapy. It has been shown to be an effective vehicle for stable and long-term gene expression. The results of this study demonstrated that the rate of lentiviral vector transducing to HaCaT cells was >90%. The real-time RT-PCR and western blot analyses indirectly indicated that the HaCaT cells transduced with the lentiviral shRNA vector expressed siRNA-targeting CDK2AP1 gene. In this study, CDK2AP1 siRNA was demonstrated to inhibit, not only P12CDK2AP1 expression, but also the activity of P12CDK2AP1 in HaCaT cells.

Previous data have demonstrated that CDK2AP1 is crucial in cancer cell proliferation (2,5,21). In this study, in order to determine whether CDK2AP1 regulated HaCaT cell proliferation and the cell cycle, transduced HaCaT cells were analyzed. The results showed that RNAi-targeting CDK2AP1 promoted the proliferation of HaCaT cells. Flow cytometric analysis showed that the inhibition of P12CDK2AP1 expression in HaCaT cells, resulted in a lower number of cells in the G1 phase of the cell cycle.

Although significant downregulation of P12CDK2AP1 expression was achieved, complete gene silencing was not achieved. It is believed that residual P12CDK2AP1 expression in the mass culture cells is due to the presence of a few clones that have completely escaped the effect of siRNA. The incomplete gene silencing of P12CDK2AP1 observed in this study could be attributed to the relatively weak expression from Pol III promoters (18–20). However, it is believed that even incomplete gene silencing would be of therapeutic utility for a number of human disease conditions. Studies are underway aiming to investigate the mechanisms underlying the incomplete gene silencing and a number of strategies could be established to improve the efficiency of this procedure.

In this study, a lentiviral vector was constructed for the delivery of siRNAs and its ability to efficiently downregulate the expression of a target gene in the infected cells was demonstrated. It was also shown that P12CDK2AP1 silencing promotes the proliferation of cultured cells. Based on the well-known ability of lentiviruses to infect dividing and non-dividing cells as well as to achieve long-term gene expression, they are an attractive option for the in vitro and in vivo delivery of siRNAs in cultured cells.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China to Professor M.S. (project nos. 81072230 and 30772428).

References

1 

Moser BA, Subramanian L, Khair L, Chang YT and Nakamura TM: Fission yeast Tel1(ATM) and Rad3(ATR) promote telomere protection and telomerase recruitment. PLoS Genet. 5:e10006222009. View Article : Google Scholar : PubMed/NCBI

2 

Shintani S, Mihara M, Terakado N, et al: Reduction of p12DOC-1 expression is a negative prognostic indicator in patients with surgically resected oral squamous cell carcinoma. Clin Cancer Res. 7:2776–2782. 2001.PubMed/NCBI

3 

Tsuji T, Duh FM, Latif F, et al: Cloning, mapping, expression, function, and mutation analyses of the human ortholog of the hamster putative tumor suppressor gene Doc-1. J Biol Chem. 273:6704–6709. 1998. View Article : Google Scholar : PubMed/NCBI

4 

Daigo Y, Suzuki K, Maruyama O, et al: Isolation, mapping and mutation analysis of a human cDNA homologous to the doc-1 gene of the Chinese hamster, a candidate tumor suppressor for oral cancer. Genes Chromosomes Cancer. 20:204–207. 1997. View Article : Google Scholar : PubMed/NCBI

5 

Todd R, McBride J, Tsuji T, et al: Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. FASEB J. 9:1362–1370. 1995.PubMed/NCBI

6 

Shintani S, Ohyama H, Zhang X, et al: p12(DOC-1) is a novel cyclin-dependent kinase 2-associated protein. Mol Cell Biol. 20:6300–6307. 2000. View Article : Google Scholar : PubMed/NCBI

7 

Matsuo K, Shintani S, Tsuji T, et al: p12(DOC-1), a growth suppressor, associates with DNA polymerase alpha/primase. FASEB J. 14:1318–1324. 2000. View Article : Google Scholar : PubMed/NCBI

8 

Yuan Z, Sotsky Kent T and Weber TK: Differential expression of DOC-1 in microsatellite-unstable human colorectal cancer. Oncogene. 22:6304–6310. 2003. View Article : Google Scholar : PubMed/NCBI

9 

Sharp PA: RNAi and double-strand RNA. Genes Dev. 13:139–141. 1999. View Article : Google Scholar : PubMed/NCBI

10 

Naldini L and Verma IM: Lentiviral vectors. Adv Virus Res. 55:599–609. 2000. View Article : Google Scholar

11 

Naldini L, Blomer U, Gage FH, Trono D and Verma IM: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA. 93:11382–11388. 1996. View Article : Google Scholar : PubMed/NCBI

12 

Naldini L, Blomer U, Gallay P, et al: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:263–267. 1996. View Article : Google Scholar : PubMed/NCBI

13 

Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI

14 

Mulholland DJ, Xin L, Morim A, Lawson D, Witte O and Wu H: Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 69:8555–8562. 2009.

15 

Todd R, Donoff RB and Wong DT: The molecular biology of oral carcinogenesis: toward a tumor progression model. J Oral Maxillofac Surg. 55:613–625. 1997. View Article : Google Scholar : PubMed/NCBI

16 

Kohno Y, Patel V, Kim Y, et al: Apoptosis, proliferation and p12(doc-1) profiles in normal, dysplastic and malignant squamous epithelium of the Syrian hamster cheek pouch model. Oral Oncol. 38:274–280. 2002. View Article : Google Scholar

17 

Shintani S, Mihara M, Nakahara Y, et al: Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol. 38:235–243. 2002. View Article : Google Scholar : PubMed/NCBI

18 

Barton GM and Medzhitov R: Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci USA. 99:14943–14945. 2002. View Article : Google Scholar : PubMed/NCBI

19 

Brummelkamp TR, Bernards R and Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2:243–247. 2002. View Article : Google Scholar : PubMed/NCBI

20 

Devroe E and Silver PA: Retrovirus-delivered siRNA. BMC Biotechnol. 2:152002. View Article : Google Scholar

21 

Sotsky Kent T, Yuan Z, Miller A and Weber TK: Deleted in oral cancer-1 expression upregulates proapoptosis elements in microsatellite-unstable human colorectal cancer. Ann Surg Oncol. 11:192–196. 2004.PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Sun M, Zheng J, Xue H, Jiang Y, Li C, Li J, Jin W, Shen M, Yang X, Ni Q, Ni Q, et al: Silencing P12CDK2AP1 with a lentivirus promotes HaCaT cell proliferation. Mol Med Rep 7: 471-475, 2013.
APA
Sun, M., Zheng, J., Xue, H., Jiang, Y., Li, C., Li, J. ... Ni, Q. (2013). Silencing P12CDK2AP1 with a lentivirus promotes HaCaT cell proliferation. Molecular Medicine Reports, 7, 471-475. https://doi.org/10.3892/mmr.2012.1205
MLA
Sun, M., Zheng, J., Xue, H., Jiang, Y., Li, C., Li, J., Jin, W., Shen, M., Yang, X., Ni, Q."Silencing P12CDK2AP1 with a lentivirus promotes HaCaT cell proliferation". Molecular Medicine Reports 7.2 (2013): 471-475.
Chicago
Sun, M., Zheng, J., Xue, H., Jiang, Y., Li, C., Li, J., Jin, W., Shen, M., Yang, X., Ni, Q."Silencing P12CDK2AP1 with a lentivirus promotes HaCaT cell proliferation". Molecular Medicine Reports 7, no. 2 (2013): 471-475. https://doi.org/10.3892/mmr.2012.1205
Copy and paste a formatted citation
x
Spandidos Publications style
Sun M, Zheng J, Xue H, Jiang Y, Li C, Li J, Jin W, Shen M, Yang X, Ni Q, Ni Q, et al: Silencing P12CDK2AP1 with a lentivirus promotes HaCaT cell proliferation. Mol Med Rep 7: 471-475, 2013.
APA
Sun, M., Zheng, J., Xue, H., Jiang, Y., Li, C., Li, J. ... Ni, Q. (2013). Silencing P12CDK2AP1 with a lentivirus promotes HaCaT cell proliferation. Molecular Medicine Reports, 7, 471-475. https://doi.org/10.3892/mmr.2012.1205
MLA
Sun, M., Zheng, J., Xue, H., Jiang, Y., Li, C., Li, J., Jin, W., Shen, M., Yang, X., Ni, Q."Silencing P12CDK2AP1 with a lentivirus promotes HaCaT cell proliferation". Molecular Medicine Reports 7.2 (2013): 471-475.
Chicago
Sun, M., Zheng, J., Xue, H., Jiang, Y., Li, C., Li, J., Jin, W., Shen, M., Yang, X., Ni, Q."Silencing P12CDK2AP1 with a lentivirus promotes HaCaT cell proliferation". Molecular Medicine Reports 7, no. 2 (2013): 471-475. https://doi.org/10.3892/mmr.2012.1205
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team